EISAI CO LTD - Dusseldorf Stock Exchang (EII DU) stock market data APIs
€24.2957
0.27(1.1%)
as of December 12, 2025
Try our APIs with
free plan!
EISAI CO LTD - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for EII.DU.
Prev. Close
24.2957
Open
24.5633
High
24.7633
Low
23.9933
52 wk Range
20.876-29.612
Market Cap
15 022 M
EPS
46.4
Dividends (Yield)
1.2903
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get EISAI CO LTD - Dusseldorf Stock Exchang data using free add-ons & libraries
Get EISAI CO LTD - Dusseldorf Stock Exchang Fundamental Data
EISAI CO LTD - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-05-14
- EPS/Forecast: 35.18
Get EISAI CO LTD - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
EISAI CO LTD - Dusseldorf Stock Exchang News
New
Leqembi included in China's commercial insurance innovative drug list
STOCKHOLM, Dec. 8, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (lecanemab), has been included in the "Commercial Insurance Innova...
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
Biogen Inc. TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: C...
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)?
In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet ...
Eisai (TSE:4523): Revisiting Valuation After Recent Share Price Rebound
Recent Share Performance and Context Eisai (TSE:4523) has quietly outperformed over the past month, even as the stock has slipped over the past 3 months and year to date. This creates an interesting ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
